Premium
Ethnic Difference in the Pharmacodynamics‐efficacy Relationship of Dipeptidyl Peptidase‐4 Inhibitors Between Japanese and non‐Japanese Patients: A Systematic Review
Author(s) -
Ito Y,
Ambe K,
Kobayashi M,
Tohkin M
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.692
Subject(s) - medicine , placebo , pharmacodynamics , dipeptidyl peptidase 4 , randomized controlled trial , diabetes mellitus , glycated hemoglobin , type 2 diabetes mellitus , type 2 diabetes , pharmacology , pharmacokinetics , endocrinology , alternative medicine , pathology
A systematic review of the differences in the efficacy of dipeptidyl peptidase‐4 (DPP‐4) inhibitors between Japanese and non‐Japanese subjects was conducted. We searched for randomized controlled trials in patients with type 2 diabetes mellitus (T2DM) that studied the intervention of a DPP‐4 inhibitor once‐daily vs. placebo, as monotherapy or as add‐on therapy. Data regarding placebo‐corrected HbA1c reduction and trough DPP‐4 inhibition rate after ≥12 weeks' treatment were extracted. In the 12 eligible studies, linear regression analysis revealed that the hemoglobin A1c (HbA1c) reduction at each DPP‐4 inhibition level was larger in studies involving Japanese patients than in studies involving non‐Japanese patients, with statistical significance between the two groups ( P < 0.0001). Sensitivity analysis excluding studies of add‐on therapies supported the robustness of the result. Our study indicated that DPP‐4 inhibitors show greater efficacy in Japanese patients than in non‐Japanese patients, which may be an important consideration in the global development strategy of new diabetic medications.